|
|
|
|
|||||
|
|
|
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143.
The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV pre-exposure prophylaxis. Flyn believes that this is a strong endorsement of the drug’s efficacy and safety. Moreover, the analyst also noted that the recommendation could lead to better patient adherence and stronger HIV prevention, thereby boosting the demand for Yeztugo.
In addition, Gilead Sciences, Inc. (NASDAQ:GILD) is also working to secure commercial insurance coverage for Yeztugo and expects to have substantial coverage in place by the end of 2025.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that develops medicines to treat serious diseases like HIV, viral hepatitis, COVID-19, and cancer.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 2 hours | |
| Sep-27 | |
| Sep-26 | |
| Sep-25 | |
| Sep-25 | |
| Sep-25 | |
| Sep-24 | |
| Sep-21 | |
| Sep-18 | |
| Sep-18 | |
| Sep-17 | |
| Sep-16 | |
| Sep-16 | |
| Sep-15 | |
| Sep-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite